Japanese biopharma majority-owned by Roche, developing antibody drugs for cancer, immunology and rare disease.
Japanese biopharma majority-owned by Roche, developing antibody drugs for cancer, immunology and rare disease.
Roche owns a majority and sells Chugai-discovered antibodies such as Actemra and Hemlibra outside Japan, paying Chugai for supply and royalties, so a large share of income comes from Roche. In Japan Chugai sells those drugs and Roche's own products itself. It has kept its listing and independence since the 2002 tie-up.
In one line: Roche's Japan-based Genentech.
Moat: narrow (IP / patents, process know-how). Roche alliance funds R&D and gives global commercial reach for Chugai-discovered antibodies.
Headquarters: Tokyo, Japan · Founded: 1925 · Employees: 7,872
Size Chugai Pharmaceutical (4519.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $75.2B, the 19th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥7,206 on 18 Nov 2026.
Performance Over six months the shares fell 8.4%, against +14.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 16.5% over the last twelve months (peer median +6.1%); the operating margin is 49.8% (peer median 24.0%).
Valuation It trades at 23.7× forward earnings against a peer median of 16.9× (8th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 32.4 points above its cost of capital (7.2% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥1.41T | ¥1.26T | ¥1.17T | ¥1.11T | ¥1.26T |
| Revenue growth | — | +7% | +5% | -12% | — |
| Gross profit | ¥1.01T | ¥894B | ¥831B | ¥693B | ¥783B |
| EBITDA | ¥745B | ¥624B | ¥576B | ¥447B | ¥565B |
| Net income | ¥504B | ¥434B | ¥387B | ¥325B | ¥374B |
| Free cash flow | ¥367B | ¥313B | ¥399B | ¥339B | ¥182B |
| Capital expenditure | ¥103B | ¥112B | ¥54.9B | ¥74.3B | ¥71.2B |
| Total debt | ¥16.1B | ¥25.7B | ¥10.9B | ¥13.5B | ¥14.1B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Chugai Pharmaceutical 4519.T | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| Daiichi Sankyo 4568.T | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 11.8× | -1.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4519.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.8% | +4.3% | 4th highest of 21 |
| 6-month return | -8.4% | +14.7% | 2nd lowest of 21 |
| Distance from 52-week high | -32.0% | -5.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | +16.5% | +6.1% | 4th highest of 21 |
| Operating margin | 49.8% | 24.0% | 2nd highest of 21 |
| Forward P/E | 23.7× | 16.9× | 8th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 5.0% | 6.2% | 9th least demanding of 20 |
| Growth delivered (Del g) | +9.8% | +6.4% | 7th highest of 20 |
| Hurdle (Req g minus delivered) | -4.8 pp | -3.4 pp | 10th least demanding of 20 |
| ROIC minus cost of capital | +32.4 pp | +4.4 pp | 2nd highest of 21 |
| EV / EBITDA | 14.9× | 11.6× | 9th most expensive of 19 |
| Net debt / EBITDA | -1.1× | 1.8× | 4th least indebted of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chugai Pharmaceutical 4519.T | Japan | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% | +9.8% |
| Merck KGaA MRK.DE | Germany | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% | +3.8% |
| Takeda Pharmaceutical 4502.T | Japan | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% | +7.1% |
| WuXi AppTec 603259.SS | China | $64.2B | +40% | +32% | 43% | 17.0× | 7.2% | +22.3% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Regeneron Pharmaceuticals REGN | United States | $97.8B | +46% | +19% | 30% | 11.8× | -1.1% | +11.0% |
| GSK GSK.L | United Kingdom | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% | -0.9% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Sanofi SAN.PA | France | $114B | +13% | +15% | 27% | 9.7× | -4.8% | +3.9% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Bristol Myers Squibb BMY | United States | $122B | +3% | +4% | 33% | 9.2× | -13.1% | +2.5% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | China | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% | +2.7% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Vertex Pharmaceuticals VRTX | United States | $136B | +25% | +11% | 35% | 28.5× | 6.2% | +14.2% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Pfizer PFE | United States | $160B | +9% | +1% | 26% | 9.9× | -4.3% | +8.5% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |